X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

分组1 - X4 Pharmaceuticals reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.36, and a significant improvement from a loss of $6.01 per share a year ago, resulting in an earnings surprise of +38.89% [1] - The company achieved revenues of $2.57 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 53.22%, compared to revenues of $1.43 million in the same quarter last year [2] - X4 Pharmaceuticals has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 11% since the beginning of the year, while the S&P 500 has declined by 2.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.23 on revenues of $4.9 million, and for the current fiscal year, it is -$1.09 on revenues of $11.25 million [7] - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]